Today, NICE has published its final guidance for the SMA treatment Spinraza.
This guidance followed the announcement by NICE and NHS England on 3 July that changes to the Managed Access Agreement (MAA) had been made following strong representation from clinicians and the patient community to reconsider MAA eligibility in line with available clinical evidence.
The guidance on Spinraza will be reviewed and published by the end of the MAA in five years.
There will be a short debate on treatment for SMA in the House of Commons on 25 July, which is set to reflect on the current MAA eligibility for Spinraza and gathering further clinical evidence in the future.
You can find out more about the MAA in our Spinraza FAQ section.